News

OBI Pharma Announces First Patient Enrolled on SWOG Cancer Research Network’s OBI-3424 Phase 1/2 Study Targeting AKR1C3 in T-ALL and T-LBL

First clinical trial to evaluate the safety and efficacy of OBI-3424, a DNA alkylating agent targeting AKR1C3 enzyme, in T-Cell Acute Lymphocytic Leukemia (T-ALL) and Lymphoblastic Lymphoma (T-LBL) TAIPEI, Taiwan, …

Poster Presentation at AACR 2021 Annual Meeting for OBI-3424, OBI-998, GLOBO H and SSEA-4

Title: Selective and Broad Anti-tumor Activity of AKR1C3-activated Prodrug AST-3424/OBI-3424 Poster Number: 1220 / Abstract number: 1062 Title: Preclinical characterization of a novel SSEA4-targeting antibody drug conjugate, OBI-998 Poster number: …

OBI Pharma Announces Poster Presentations at AACR 2021 Annual Meeting for OBI-3424, OBI-998, Globo H and SSEA-4

Poster Presentations to highlight the latest research on OBI-3424 (AKR1C3 small molecule pro-drug), OBI-998 (SSEA-4 ADC) and the glycosphingolipid cancer antigens, Globo H and SSEA-4. Taipei, Taiwan. April 06, 2021 …

OBI Pharma, Inc. to Present at the 39th J.P. Morgan Healthcare Conference

Taipei, Taiwan. January 6, 2021 — OBI Pharma, Inc., a Taiwan biopharma company (TPEx: 4174), announced that Tillman Pearce, MD., Chief Medical Officer, will present a company and clinical development …

ESMO Asia 2020 Virtual Annual Meeting for OBI-833, a Novel Anti-Globo H Targeted Therapeutic Cancer Vaccine

1. Presentation number: 397P / Poster: ID 680 Title: A phase I cohort expansion trial of OBI-833 in non-small cell lung cancer patients Presenter: Ching-Liang Ho MD, et.al. Department of …

OBI Pharma Announces Presentations at ESMO Asia 2020 Virtual Annual Meeting for OBI-833, a Novel Anti-Globo H Targeted Therapeutic Cancer Vaccine

Presentations to highlight the OBI-833 Phase 1 clinical study results in non-small cell lung cancer (NSCLC) and the dose escalation cohort TAIPEI, Taiwan, November 19, 2020/PRNewswire/OBI Pharma, Inc. (TPEx: 4174), …

Company Announcement on Board Resolutions

Please refer to http://www.obipharma.com/2020/09/company-announcement-on-board-resolution/?lang=zh-hant for details.

OBI Pharma Announces OBI-999 Presentation at 2020 World ADC Digital Meeting

Presentation to highlight the scientific characteristics of the novel first-in-class anti Globo H antibody-drug conjugate (ADC), OBI-999. TAIPEI, Taiwan, Sept 14, 2020/PRNewswire/OBI Pharma, Inc. (TPEx: 4174), a leader in Glycosphingolipid …

Poster Presentations at AACR 2020 Virtual Annual Meeting II

Session PO ET04.02 Identification of molecular targets 2 Title: The role of Globo H in cancer cell survival Presenter: Tzer-Min Kuo, PhD, et. al., OBI Pharma, Inc., Taipei, Taiwan Virtual …

OBI Pharma Announces Poster Presentations at AACR 2020 Virtual Annual Meeting II

Poster Presentations to highlight the role of the Globo H antigen in cancer cell survival and its prevalence in different tumor types TAIPEI, Taiwan, June 16, 2020/PRNewswire/OBI Pharma, Inc. (TPEx: …